June 3rd 2021 Recently, the FDA approved an Amgen drug, sotorasib, for non-small cell lung cancer (NSCLS) with a specific mutation in a gene known as Kirsten rat sarcoma viral oncogene homolog (KRAS) in patients whose disease has worsened after treatment with chemotherapy or other medicines. This mutation accounts for 13% of NSCLS—the most common … Continue reading FDA approves lung cancer drug #MPAR